5 Best Biotech Stocks Under $5

4. Curis, Inc. (NASDAQ:CRIS)

Number of Hedge Fund Holders: 20

Share Price as of March 28: $2.3900

Curis, Inc. (NASDAQ:CRIS) is a Massachusetts-based biotechnology company that develops drug candidates for the treatment of human cancers. The company is currently in the clinical stages of discovering treatments for non-hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes. The Q4 revenue of $3.14 million outperformed estimates by $203,200. 

On March 2, Cantor Fitzgerald analyst Alethia Young maintained an Overweight rating on Curis, Inc. (NASDAQ:CRIS), while lowering the price target to $12 from $24. According to the analyst, while Curis, Inc. (NASDAQ:CRIS) shares have been under pressure in the past six months, key catalysts could receive regulatory clarity given significant development and more data in patients.

According to the fourth quarter database of Insider Monkey, 20 funds were bullish on Curis, Inc. (NASDAQ:CRIS), compared to 21 funds in the preceding quarter. Lee Ainslie’s Maverick Capital is the leading shareholder of the company, with 7.7 million shares worth $37 million.